Two thirds of the recipients received an additional induction therapy, i.e., IL2-RA (59.1% ADPKD vs. 53.9% control) or in immunized recipients ATG (6.2% ADPKD vs. 5.7% control). This evidence concerns the gene IL2 and autosomal dominant polycystic kidney disease.